Cellectar Biosciences Stock
Cellectar Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- James V. Caruso
- Employees
- 11
- Market cap
- $11 M
- IPO
- 10/11/2005
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in…
Cellectar Biosciences stock: price history
1D
-4.2%
1W
-21.4%
1M
-51.5%
6M
-61.0%
YTD
-61.4%
1Y
-76.0%
2Y
-98.2%
5Y
-99.6%
10Y
-100.0%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~33% weaker price swings than usual
Ask the agents about Cellectar Biosciences
Analyst assessment of Cellectar Biosciences
PRICE TARGET LOW
US$11.00
CONSENSUS
US$11.00
MEDIAN
US$11.00
PRICE TARGET HIGH
US$11.00
0
STRONG BUY
7
BUY
1
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 10/03/2026
Cellectar Biosciences stock metrics
P/E
-0.25
P/B
0.47
EV/EBITDA
0.97
RETURN ON EQUITY
-23.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.05
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
98.2%
FLOAT SHARES
9,278,756
AVG. DAILY VOLUME (30D)
122,268
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Cellectar Biosciences stock
What does Cellectar Biosciences do?
Cellectar Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is James V. Caruso, the company employs around 11 people.
The IPO was on 10/11/2005; the stock trades on NASDAQ under the ticker CLRB.
What do analysts say about Cellectar Biosciences stock?
8 analysts rate the stock, the consensus is Buy (as of 10/03/2026).
The average price target is US$11.00, ranging from US$11.00 to US$11.00, with a median of US$11.00.
This is an external assessment, not a statement by Market Jury.
When does Cellectar Biosciences report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -33% stronger than usual.
Does Cellectar Biosciences pay a dividend?
No, Cellectar Biosciences currently does not pay a dividend.
Which stocks are comparable to Cellectar Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Cellectar Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cellectar Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.